Insider trade

Officer sold ~$267K of ALKS shares in the open market

Traded Mar 2, 2026 · Filed Mar 5, 2026

Why it stands out

Alkermes's R&D, Chief Medical Officer sold $267K of Alkermes shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$267,485

Shares × reported transaction price

Timing vs results

5 days after results of Feb 25, 2026, 64 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−2.5%	−2.2%	−0.3%
30 days	+20.2%	−3.3%	+23.5%
90 days	+50.8%	+10.7%	+40.1%
180 days	+66.5%	+11.8%	+54.7%

Past results only. Not a forecast.

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.29 to $30.13. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

6mo ago

Derivative exercise or conversion — not an open-market buy.

Scheduled in advance6mo ago

6mo ago

Derivative exercise or conversion — not an open-market buy.